The company also reported its first-quarter result of FY21 on Tuesday where it recorded revenue of Rs 32.24 crore as against Rs 35.87 crore in Q1FY20. It posted PAT of Rs 8.63 crore in the quarter as against Rs 10.04 crore in Q1FY20

Shivalik Rasayan Limited is one of the few outperforming small-cap stocks in the agrochemical sector that has beaten Sensex as well as its industry peers by a huge margin.

During July 2020, the company has managed to achieve a healthy performance amid the current uncertain situation due to COVID-19. The company’s production and sales volume stood at 2.19 MT and 2.57 MT, showing growth by 13 per cent and 7 per cent, respectively on a YoY basis.

On the downside, immediate support is seen around 10,974 levels, where the 20-DMA is placed and it becomes important to hold above this significant short-term average to maintain a bullish bias. Stocks in news: Persistent Systems, SRF, NMDC, Paushak, Axis Bank.

The Indian markets are likely to carry a positive baton from its previous trading sessions. Early trends in SGX Nifty suggests that Nifty may open around 11,089.50 level, up by 17.50 points. However, the sombre global cues and the rigid resistance zone of 11,112 to 11,170 might keep the up-move under check.

The consolidated net sales reported in Q1FY21 came in at Rs 2,713.91 crore, which increased by 13.44 per cent YoY from Rs 2,392.36 crore in Q1FY20.

On Tuesday, L&T Technology Services Limited announced that it has expanded its collaboration with Microsoft Corporation and launched the latest & enhanced version of the state-of-the-art i-BEMS™ solution on Microsoft Azure in order to transform buildings into future-ready smart campuses.

Ending a four-day losing streak, bulls made a comeback on Tuesday as Sensex gained by 748.31 points or 2.03 per cent to close at 37,687.91 while its NSE counterpart, Nifty rose by 211.25 points or 1.94 per cent to settle at 11,102.85.

Favipiravir is the only oral anti-viral treatment approved in India for the potential treatment of patients with mild to moderate COVID-19 disease.

The consolidated net sales reported in Q2CY20 came in at Rs 1,665.69 crore, which declined by 41.58 per cent YoY from Rs 2,851.459 crore in Q2CY19.